Ken Griffin Aadi Bioscience, Inc. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 28,538 shares of AADI stock, worth $48,799. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,538

Previous 2,600 997.62%

Holding current value

$48,799

Previous $4,000 1100.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$1.58 - $1.71 $108,662 - $117,603	-68,774 Reduced 70.67%	28,538 $48,000
Q1 2025 May 15, 2025	BUY	$1.78 - $3.73 $62,793 - $131,583	35,277 Added 56.87%	97,312 $173,000
Q4 2024 Feb 14, 2025	BUY	$1.92 - $3.39 $104,814 - $185,063	54,591 Added 733.36%	62,035 $196,000
Q3 2024 Nov 14, 2024	SELL	$1.32 - $2.06 $641,113 - $1 Million	-485,692 Reduced 98.49%	7,444 $15,000
Q2 2024 Aug 14, 2024	SELL	$1.46 - $2.31 $35,682 - $56,456	-24,440 Reduced 4.72%	493,136 $719,000
Q1 2024 May 15, 2024	BUY	$1.59 - $2.44 $174,667 - $268,043	109,854 Added 26.94%	517,576 $1.21 Million
Q4 2023 Feb 14, 2024	BUY	$1.97 - $5.41 $337,768 - $927,576	171,456 Added 72.57%	407,722 $823,000
Q3 2023 Nov 14, 2023	SELL	$4.84 - $7.13 $109,514 - $161,330	-22,627 Reduced 8.74%	236,266 $1.14 Million
Q2 2023 Aug 14, 2023	SELL	$6.84 - $8.56 $245,556 - $307,304	-35,900 Reduced 12.18%	258,893 $1.77 Million
Q1 2023 May 15, 2023	SELL	$6.85 - $13.0 $15,076 - $28,613	-2,201 Reduced 0.74%	294,793 $2.13 Million
Q4 2022 Feb 14, 2023	BUY	$11.99 - $14.5 $443,318 - $536,123	36,974 Added 14.22%	296,994 $3.81 Million
Q3 2022 Nov 14, 2022	BUY	$12.03 - $14.22 $321,982 - $380,598	26,765 Added 11.47%	260,020 $3.67 Million

Others Institutions Holding AADI

# of Institutions

Shares Held

30M

Call Options Held

Put Options Held

View Full List

About Aadi Bioscience, Inc.

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $35.9M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

More about AADI

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account